Rezera Inc. (RZRA)

This company has not started trading yet. The live 5-factor QL signal switches on automatically on its first session.

About Rezera Inc.

We are a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly owned oral inhibitors of NLRP3. NLRP3 is the upstream driver of sterile inflammation – inflammation that is caused by damage signals, such as cholesterol crystals or misfolded proteins, rather than by infection.

From Rezera Inc.'s Form S-1/A filed with the SEC on 2026-11-05. The issuer's own words — QuantLogix does not paraphrase it.

Industry

Pharmaceutical Preparations

Headquarters

Boston, MA

Incorporated in

Delaware

Fiscal year ends

December 31

SEC filer

CIK 0002141583

The offering

Ticker

RZRA

Exchange

XNAS

Expected listing

To be announced

Expected price range

$11–$13

Deal size

$230M

gross proceeds

Shares offered

16,666,667

Share class

Healthcare

Use of proceeds

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, plus the proceeds from the issuance of the Series D4 Stock and the Term Loan, to advance ruvonoflast through topline data from our proposed Phase 3 clinical trial in PAD, which we expect in 2028, and for general corporate purposes.

From Rezera Inc.'s Form S-1/A filed with the SEC on 2026-11-05. Quoted from the prospectus.

Financials, as filed

Net loss	$42,200,000	year ended December 31, 2025vs $25,200,000 · year ended December 31, 2024	+67.5%

Figures as stated in the prospectus, not QuantLogix estimates. From Rezera Inc.'s Form S-1/A filed with the SEC on 2026-11-05.

Risks Rezera Inc. flags in its own filing

We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.
As part of our ongoing business, we will need to raise substantial additional funding beyond our current capital.
We currently rely, and plan to rely in the future, on third parties to conduct our clinical trials for our current and future product candidates.
We have identified material weaknesses in our internal control over financial reporting.

The first 4 items of the issuer's “Summary of Risk Factors”, verbatim — the prospectus lists more. From Rezera Inc.'s Form S-1/A filed with the SEC on 2026-11-05.

QL Listing Score — the prospectus, scored

45/100

Challenged · medium confidence

The evolution of the private-company QL Score at the point of listing: four evidence pillars read deterministically from the registration statement — growth, revenue quality, technology and risk — weights frozen per version (v1.1.0), pillars with no evidence excluded and reweighted, never defaulted.

Growth60

issuer states a $5B market opportunity

Revenue qualityno evidence — excluded

Technology75

technology-language density 12.9/10k words (lexical indicator, not a technical audit)

Risk15

auditor states substantial doubt about going concern · material weakness in internal controls disclosed

Foundationno evidence — excluded

⚠ Going-concern doubt disclosed⚠ Material weakness in controls✓ Single share class✓ No customer-concentration flag◆ Emerging growth company (reduced disclosure)◆ Issuer states a $5B market opportunity

From Rezera Inc.'s Form S-1/A filed with the SEC on 2026-11-05. Extraction is deterministic — the same filing always produces the same score; 492k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.

Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.

Full IPO calendar → ⭐ Track RZRA — first-signal alert on listing day Pre-IPO universe →